University of Louisville homepage
All experts
All experts

Kristina Bryant

Professor

School of Medicine

Orcid identifier0000-0003-0228-1777
  • Professor
    School of Medicine

SPONSORED PROJECTS

  • Showing page 1 out of 1
Showing page 1, sponsored projects 1 to 15 of 15
GRANT
AWD-00000073|SkySavi5: A Phase 3, Randomized, Modified Double-Blind, Active-Controlled, Parallel-Group, 2-Arm Study to Investigate the Safety of a 4-Dose Regimen of a 21-Aalent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers
Sanofi Research1 Jan 2025
MORELEARN MORE
GRANT
240244|Leveraging Implementation and Behavioral Science to Reduce Harmful Overuse of Diagnostic Testing in Critically Ill Children.
Childrens Hospital of Philadelphia_CHOP1 Jan 2023
MORELEARN MORE
GRANT
230913|Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium (RDCRC): Targeted Clinical Research to Address Select Viral Infections
Univ of Alabama at Birmingham_UAB9 Jan 2022
MORELEARN MORE
GRANT
220914|A Phase 2/3, Interventional Safety, Pharmacokinetics & Eff OL, MC, Single-Arm, St to Investigate Orally Administered Nirmatrelvir/Ritonavir in Non-Hospitalized Symptomatic Pediatric Participants w COVID-19 Who are at Risk of Progression to Severe Disease
Parexel International Corporation_PIC1 Jan 2022
MORELEARN MORE
GRANT
211017|Center for Pediatric Everyday Readiness: HRSA 21-104 Regional Pediatric Pandemic Network
Univ Hospitals Cleveland Medic Ctr_UHCMC9 Jan 2021
MORELEARN MORE
GRANT
210769|Phase 1 Open-Label Dose-Finding Study To Evaluate Safety, Tolerability & Immunogenicity, And Phase 2/3 Placebo-Controlled, Observer-Blinded Safety Tolerability & Immunogenicity Study Of A SARS-COV-2 RNA Vac Candidate Against COV-19 In Hlthy Children < 12
Pfizer Inc_PFIZER5 Jan 2021
MORELEARN MORE
GRANT
210436|A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734?) in Participants from Birth to < 18 Years of Age with COVID-19.
Gilead Sciences Inc_GSI2 Jan 2021
MORELEARN MORE
GRANT
210696|Phase 2 Randomized, Double Blink, Placebo-Controlled, 2 Part Study to Evaluate EDP-938 (A Novel Non-Fusion RSV Inhibitor) Regimens in Subjects Aged 28 Days to 24 Months, Infected with Respiratory Syncytial Virus (RSV).
Enanta Pharmaceuticals Inc _EPI1 Jan 2021
MORELEARN MORE
GRANT
201157|B7471011: A Phase 3, Randomized, Double-Blind Trial To Evaluate The Safety And Immunogenicity Of A 20-Valent Pneumococcal Conjugate Vaccine In Healthy Infants
ICON Clinical Research_ICON1 Jan 2020
MORELEARN MORE
GRANT
200792C1 | GB DMID 20-0033 Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium (RDCRC)
Univ of Alabama at Birmingham_UAB9 Jan 2019
MORELEARN MORE
GRANT
200792C1 | GN DMID 20-0033 Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium (RDCRC)
Univ of Alabama at Birmingham_UAB9 Jan 2019
MORELEARN MORE
GRANT
200792C| GB DMID 19-0026 Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium (RDCRC)
Univ of Alabama at Birmingham_UAB9 Jan 2019
MORELEARN MORE
GRANT
200792C| GN DMID 19-0026 Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium (RDCRC)
Univ of Alabama at Birmingham_UAB9 Jan 2019
MORELEARN MORE
GRANT
200792|A PROSPECTIVE STUDY OF ACUTE FLACCID MYELITIS (AFM) TO DEFINE NATURAL HISTORY, RISK FACTORS, AND PATHOGENETIC MECHANISMS
Univ of Alabama at Birmingham_UAB9 Jan 2019
MORELEARN MORE
GRANT
200792|Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium (RDCRC)
Univ of Alabama at Birmingham_UAB9 Jan 2019
MORELEARN MORE